Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...

The study compared CARVYKTI's efficacy and safety against standard-of-care regimens in patients with multiple myeloma.

The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R ...

Multiple myeloma (MM) is a malignant plasma cell disorder ... and the proteasome inhibitor bortezomib. [1] IMiDs are structural and functional analogs of thalidomide that have potent ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

GSK continues to build the case for its multiple myeloma therapy Blenrep ... to Darzalex given on top of Takeda’s Velcade (bortezomib) plus dexamethasone (BorDex) as second-line therapy.

Dosage for adults whose previous treatments with certain other drugs didn’t work well Darzalex is used along with bortezomib and dexamethasone in adults previously treated for multiple myeloma ...

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI® reduced the risk of disease progression or death by 74 per cent compared to ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced abstracts detailing selinexor data have been selected to be ...

CARTITUDE-4 compared Carvykti to a pair of three-drug multiple myeloma regimens – pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd ...